Abstracts tagged "glucocorticoids"

Abstract Number: 0203 • ACR Convergence 2024
Agreement of Administrative Pharmacy Dispensing with Patient-Reported Use of Oral Glucocorticoids in a Rheumatoid Arthritis Cohort
Beth Wallace¹, Bryant England², Joshua Baker³, Sauer brian⁴, Jorge Rojas⁵, Punyasha Roul⁶, Michael George⁷, Katherine Wysham⁸, Hannah Brubeck⁹, Isaac Smith¹⁰, Liron Caplan¹¹, Paul Monach¹², Gail Kerr¹³, Gary Kunkel¹⁴, Tawnie Braaten¹⁵, Ted Mikuls² and grant Cannon¹⁶, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Seattle VA, Mexico, Mexico, ⁶UNMC, Omaha, NE, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹VA Puget Sound Health Care System, Seattle, WA, ¹⁰Duke Department of Medicine; VA Durham Healthcare System, Durham, NC, ¹¹Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ¹²VA Boston Healthcare System, Boston, MA, ¹³Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁴University of Utah/VA Salt Lake City Health Care, Salt Lake City, UT, ¹⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ¹⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Administrative claims are often used to evaluate oral glucocorticoid (GC) use in RA for clinical and research purposes, despite limited evidence to support their…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…
Abstract Number: 2032 • ACR Convergence 2024
A Systematic Review of Treatment Strategies in VEXAS Syndrome
Aviraag Vijaya Prakash¹, Jose Garcia², Anurag Goel³, Vinit Gilvaz⁴ and Raveena Midha⁵, ¹Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, ²Brown University, East Greenwich, RI, ³The Warren Alpert Medical School of Brown University, Providence, RI, ⁴The Warren Alpert Medical School of Brown University, East Providence, RI, ⁵Kent Hospital/Brown University, Warwick, RI
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene.…
Abstract Number: 2501 • ACR Convergence 2024
Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Rohit Vijjhalwar¹, Vithushanan Ketheeswaranathan², Aman More², Rajinder Andev³ and Shirish Dubey⁴, ¹University of Oxford, Staines, United Kingdom, ²Medical Sciences Division, University of Oxford, Oxford, United Kingdom, ³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom
Background/Purpose: Non-infectious Aortitis is a rare form of large vessel vasculitis which has a high risk of complications1. There is limited data on the management…
Abstract Number: 0295 • ACR Convergence 2024
Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Namitha Nair¹, Leen Al Saleh², Haya Haddad³, Maria Jaimes Reyes⁴, Vishakha Chetram⁵, Farooq Sheikh⁶, FLORINA CONSTANTINESCU⁷ and Anjani Pillarisetty⁸, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Watson Clinic, Lakeland, FL, ³Medstar Washington Hospital Center, Silver Spring, MD, ⁴Medstar Washington Hospital Center/Georgetown University, Washington, DC, ⁵Inova Schar Heart and Vascular, Falls Chirch, VA, ⁶MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, ⁷MedStar Washington Hospital Center, Washington, DC, ⁸Carson Tahoe Medical Group, Reno, NV
Background/Purpose: Cardiac involvement is seen in approximately a fourth of patients with sarcoidosis, a non-necrotizing granulomatous systemic disease. Among these patients, 25% may have isolated cardiac…
Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Mawuena Binka¹, Rana Muhammad Qasim Khan², Joseph Tkacz³, Donna McMorrow³, Laurence Gozalo³ and Gail Kerr⁴, ¹BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, ³Inovalon, Bowie, MD, ⁴Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
Abstract Number: 2139 • ACR Convergence 2024
Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro
Johannes Plank¹, Moritz Pfeiffenberger¹, Alexandra Damerau¹, Timo Gaber¹ and FRANK HARTMUT DR. BUTTGEREIT², ¹Charité-Universitätsmedizin Berlin, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, often leading to pain, fractures and reduced mobility in…
Abstract Number: 2503 • ACR Convergence 2024
Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben
Frank S Czerwiec¹, Irina Bancos², Paul M Stewart³, Ketan Desai¹ and David A Katz¹, ¹Sparrow Pharmaceuticals, Portland, OR, ²Mayo Clinic, Rochester, MN, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Approximately 1% of the population rely on chronic glucocorticoid (GC) prescription to control autoimmune and inflammatory conditions. Risk of GC induced adrenal insufficiency (GC-AI)…
Abstract Number: 0664 • ACR Convergence 2024
Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Hiromichi Tamaki⁴, Mitsumasa Kishimoto⁵ and Masato Okada⁴, ¹St. Luke's International Hospital, Tokyo, Tokyo, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoid is a critical treatment option for systemic lupus erythematosus (SLE). However, long-term use is associated with numerous side effects and an increased risk…
Abstract Number: 1519 • ACR Convergence 2024
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Chunhui Chen¹, Emily Wu², Huong Do³ and Kyriakos Kirou³, ¹New York Presbyterian Queens, Flushing, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
Abstract Number: 2150 • ACR Convergence 2024
Understanding Unmet Needs and Quality of Life Impact of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) Using Social Media: A Patient and Caregiver Perspective
Pallavi Arun¹, Nikita Parashar¹, Sakshi Sharma¹, Kanika Arora¹, Vandana Padmanabhan¹ and Alvaro Arjona², ¹Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ²Novartis Farmaceutica, S.A., Madrid, Madrid, Spain
Background/Purpose: Analyzing social media conversations of patients (pts) and caregivers can be useful to understand the real-world perspectives thereby improving quality of healthcare.1 GCA and…
Abstract Number: 2509 • ACR Convergence 2024
Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
Benjamin Turturice¹, Alice Fike¹, Bhavisha Patel², Emma Groarke², Karyssa Stonick¹, Shanni Liu¹, Wendy Goodspeed¹, Kaitlin Quinn¹, Neal Young² and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS is a multisystem autoinflammatory disorder due to somatic mutations in UBA1. The disease is characterized by ineffective hematopoiesis with increased risk of transfusion…
Abstract Number: 0747 • ACR Convergence 2024
Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica
FRANK HARTMUT DR. BUTTGEREIT¹, Andrea Everding², Ioana Andreica³, Herbert Kellner⁴, Florian Schuch⁵, Tonya K Marmon⁶, Frank S Czerwiec⁷, Ketan Desai⁸ and David A Katz⁹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Hamburger Rheuma Forschungszentrum II, Hamburg, Germany, ³Rheumazentrum Ruhrgebiet, Bochum, Germany, ⁴Schwerpunktpraxis f�r Rheumatologie und Gastroenterologie, Munich, Germany, ⁵PGRN, Erlangen, Germany, ⁶Marmon Biostatistics, Seattle, WA, ⁷Sparrow Pharmaceuticals, Portand, OR, ⁸IMC, Easton, PA, ⁹Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) differentially regulates intracellular glucocorticoid levels in the immune system and glucocorticoid toxicity target organs. Clofutriben is a potent HSD-1…
Abstract Number: 1532 • ACR Convergence 2024
Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In October 2023, EULAR released updated recommendations for the management of SLE2. Notably, since the previous guidelines update in 2019, anifrolumab received approval for…
Abstract Number: 2172 • ACR Convergence 2024
A Novel Cohort to Assess Longitudinal Glucocorticoid Toxicity in Individuals with Rheumatic Diseases: Objectives, Design, and Initial Baseline Characteristics
Naomi Patel¹, Miao Lin¹, Bohang Jiang¹, Isha Jha¹, Grace McMahon¹, Aubree E. McMahon¹, Yuqing Zhang², Hyon K. Choi³, Zachary Wallace⁴ and John Stone⁵, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Lexington, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GC) are a backbone of treatment regimens for many rheumatic diseases despite their association with toxicities that contribute to excess morbidity and mortality.…

1
2
3
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].